Minicircle DNA vector expressing interferon-lambda-3 inhibits hepatitis B virus replication and expression in hepatocyte-derived cell line
Background Interferon-alpha (IFNα) is a first-line treatment option for chronic hepatitis B virus (HBV) infection, but the severe systemic side-effects limited its clinical application. Interferon-lambda (IFNλ) with comparable antiviral activity and less toxic side-effects is thought to be a good al...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Guo, Xiaoyan [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2020 |
|---|
| Schlagwörter: |
|---|
| Anmerkung: |
© The Author(s) 2020 |
|---|
| Übergeordnetes Werk: |
Enthalten in: BMC cell biology - London : BioMed Central, 2000, 21(2020), 1 vom: 18. Feb. |
|---|---|
| Übergeordnetes Werk: |
volume:21 ; year:2020 ; number:1 ; day:18 ; month:02 |
| Links: |
|---|
| DOI / URN: |
10.1186/s12860-020-00250-9 |
|---|
| Katalog-ID: |
SPR026940957 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR026940957 | ||
| 003 | DE-627 | ||
| 005 | 20230519230710.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 201007s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s12860-020-00250-9 |2 doi | |
| 035 | |a (DE-627)SPR026940957 | ||
| 035 | |a (SPR)s12860-020-00250-9-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Guo, Xiaoyan |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Minicircle DNA vector expressing interferon-lambda-3 inhibits hepatitis B virus replication and expression in hepatocyte-derived cell line |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © The Author(s) 2020 | ||
| 520 | |a Background Interferon-alpha (IFNα) is a first-line treatment option for chronic hepatitis B virus (HBV) infection, but the severe systemic side-effects limited its clinical application. Interferon-lambda (IFNλ) with comparable antiviral activity and less toxic side-effects is thought to be a good alternative interferon to IFNα. Additionally, the gene vector mediated sustainably expression of therapeutic product in the target cells/tissue may overcome the shortcomings resulted from the short half-life of IFNs. Results We constructed a liver-specific IFNλ3-expressing minicircle (MC) vector under the control of a hepatocyte-specific ApoE promoter (MC.IFNλ3) and investigated its anti-HBV activity in a HBV-expressing hepatocyte-derived cell model (HepG2.2.15). As expected, the MC.IFNλ3 vector capable of expressing IFNλ3 in the recipient hepatocytes has demonstrated robust anti-HBV activity, in terms of suppressing viral antigen expression and viral DNA replication, via activation the interferon-stimulated gene (ISG) expression in HepG2.2.15 cells. Conclusions Given the MC vector can be easily delivered into liver, the liver-targeted IFN gene-transfer (MC.IFNλ3), instead of systemic administrating IFN repeatedly, provides a promising concept for the treatment of chronic HBV infection. | ||
| 650 | 4 | |a Minicircle DNA |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Type III interferon |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Interferon-stimulated gene |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Hepatitis B virus |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Chen, Dianke |4 aut | |
| 700 | 1 | |a Cai, Qingxian |4 aut | |
| 700 | 1 | |a Huang, Zhanlian |4 aut | |
| 700 | 1 | |a Xu, Wenxiong |4 aut | |
| 700 | 1 | |a Peng, Liang |4 aut | |
| 700 | 1 | |a Chen, Ping |0 (orcid)0000-0003-0131-6499 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t BMC cell biology |d London : BioMed Central, 2000 |g 21(2020), 1 vom: 18. Feb. |w (DE-627)326644830 |w (DE-600)2041486-9 |x 1471-2121 |7 nnns |
| 773 | 1 | 8 | |g volume:21 |g year:2020 |g number:1 |g day:18 |g month:02 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1186/s12860-020-00250-9 |z kostenfrei |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a GBV_ILN_11 | ||
| 912 | |a GBV_ILN_22 | ||
| 912 | |a GBV_ILN_2003 | ||
| 912 | |a GBV_ILN_2008 | ||
| 912 | |a GBV_ILN_2021 | ||
| 912 | |a GBV_ILN_4305 | ||
| 951 | |a AR | ||
| 952 | |d 21 |j 2020 |e 1 |b 18 |c 02 | ||
| author_variant |
x g xg d c dc q c qc z h zh w x wx l p lp p c pc |
|---|---|
| matchkey_str |
article:14712121:2020----::iiicenvcoepesnitreolmd3niiseaiibiurpiainnepes |
| hierarchy_sort_str |
2020 |
| publishDate |
2020 |
| allfields |
10.1186/s12860-020-00250-9 doi (DE-627)SPR026940957 (SPR)s12860-020-00250-9-e DE-627 ger DE-627 rakwb eng Guo, Xiaoyan verfasserin aut Minicircle DNA vector expressing interferon-lambda-3 inhibits hepatitis B virus replication and expression in hepatocyte-derived cell line 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © The Author(s) 2020 Background Interferon-alpha (IFNα) is a first-line treatment option for chronic hepatitis B virus (HBV) infection, but the severe systemic side-effects limited its clinical application. Interferon-lambda (IFNλ) with comparable antiviral activity and less toxic side-effects is thought to be a good alternative interferon to IFNα. Additionally, the gene vector mediated sustainably expression of therapeutic product in the target cells/tissue may overcome the shortcomings resulted from the short half-life of IFNs. Results We constructed a liver-specific IFNλ3-expressing minicircle (MC) vector under the control of a hepatocyte-specific ApoE promoter (MC.IFNλ3) and investigated its anti-HBV activity in a HBV-expressing hepatocyte-derived cell model (HepG2.2.15). As expected, the MC.IFNλ3 vector capable of expressing IFNλ3 in the recipient hepatocytes has demonstrated robust anti-HBV activity, in terms of suppressing viral antigen expression and viral DNA replication, via activation the interferon-stimulated gene (ISG) expression in HepG2.2.15 cells. Conclusions Given the MC vector can be easily delivered into liver, the liver-targeted IFN gene-transfer (MC.IFNλ3), instead of systemic administrating IFN repeatedly, provides a promising concept for the treatment of chronic HBV infection. Minicircle DNA (dpeaa)DE-He213 Type III interferon (dpeaa)DE-He213 Interferon-stimulated gene (dpeaa)DE-He213 Hepatitis B virus (dpeaa)DE-He213 Chen, Dianke aut Cai, Qingxian aut Huang, Zhanlian aut Xu, Wenxiong aut Peng, Liang aut Chen, Ping (orcid)0000-0003-0131-6499 aut Enthalten in BMC cell biology London : BioMed Central, 2000 21(2020), 1 vom: 18. Feb. (DE-627)326644830 (DE-600)2041486-9 1471-2121 nnns volume:21 year:2020 number:1 day:18 month:02 https://dx.doi.org/10.1186/s12860-020-00250-9 kostenfrei Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_11 GBV_ILN_22 GBV_ILN_2003 GBV_ILN_2008 GBV_ILN_2021 GBV_ILN_4305 AR 21 2020 1 18 02 |
| spelling |
10.1186/s12860-020-00250-9 doi (DE-627)SPR026940957 (SPR)s12860-020-00250-9-e DE-627 ger DE-627 rakwb eng Guo, Xiaoyan verfasserin aut Minicircle DNA vector expressing interferon-lambda-3 inhibits hepatitis B virus replication and expression in hepatocyte-derived cell line 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © The Author(s) 2020 Background Interferon-alpha (IFNα) is a first-line treatment option for chronic hepatitis B virus (HBV) infection, but the severe systemic side-effects limited its clinical application. Interferon-lambda (IFNλ) with comparable antiviral activity and less toxic side-effects is thought to be a good alternative interferon to IFNα. Additionally, the gene vector mediated sustainably expression of therapeutic product in the target cells/tissue may overcome the shortcomings resulted from the short half-life of IFNs. Results We constructed a liver-specific IFNλ3-expressing minicircle (MC) vector under the control of a hepatocyte-specific ApoE promoter (MC.IFNλ3) and investigated its anti-HBV activity in a HBV-expressing hepatocyte-derived cell model (HepG2.2.15). As expected, the MC.IFNλ3 vector capable of expressing IFNλ3 in the recipient hepatocytes has demonstrated robust anti-HBV activity, in terms of suppressing viral antigen expression and viral DNA replication, via activation the interferon-stimulated gene (ISG) expression in HepG2.2.15 cells. Conclusions Given the MC vector can be easily delivered into liver, the liver-targeted IFN gene-transfer (MC.IFNλ3), instead of systemic administrating IFN repeatedly, provides a promising concept for the treatment of chronic HBV infection. Minicircle DNA (dpeaa)DE-He213 Type III interferon (dpeaa)DE-He213 Interferon-stimulated gene (dpeaa)DE-He213 Hepatitis B virus (dpeaa)DE-He213 Chen, Dianke aut Cai, Qingxian aut Huang, Zhanlian aut Xu, Wenxiong aut Peng, Liang aut Chen, Ping (orcid)0000-0003-0131-6499 aut Enthalten in BMC cell biology London : BioMed Central, 2000 21(2020), 1 vom: 18. Feb. (DE-627)326644830 (DE-600)2041486-9 1471-2121 nnns volume:21 year:2020 number:1 day:18 month:02 https://dx.doi.org/10.1186/s12860-020-00250-9 kostenfrei Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_11 GBV_ILN_22 GBV_ILN_2003 GBV_ILN_2008 GBV_ILN_2021 GBV_ILN_4305 AR 21 2020 1 18 02 |
| allfields_unstemmed |
10.1186/s12860-020-00250-9 doi (DE-627)SPR026940957 (SPR)s12860-020-00250-9-e DE-627 ger DE-627 rakwb eng Guo, Xiaoyan verfasserin aut Minicircle DNA vector expressing interferon-lambda-3 inhibits hepatitis B virus replication and expression in hepatocyte-derived cell line 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © The Author(s) 2020 Background Interferon-alpha (IFNα) is a first-line treatment option for chronic hepatitis B virus (HBV) infection, but the severe systemic side-effects limited its clinical application. Interferon-lambda (IFNλ) with comparable antiviral activity and less toxic side-effects is thought to be a good alternative interferon to IFNα. Additionally, the gene vector mediated sustainably expression of therapeutic product in the target cells/tissue may overcome the shortcomings resulted from the short half-life of IFNs. Results We constructed a liver-specific IFNλ3-expressing minicircle (MC) vector under the control of a hepatocyte-specific ApoE promoter (MC.IFNλ3) and investigated its anti-HBV activity in a HBV-expressing hepatocyte-derived cell model (HepG2.2.15). As expected, the MC.IFNλ3 vector capable of expressing IFNλ3 in the recipient hepatocytes has demonstrated robust anti-HBV activity, in terms of suppressing viral antigen expression and viral DNA replication, via activation the interferon-stimulated gene (ISG) expression in HepG2.2.15 cells. Conclusions Given the MC vector can be easily delivered into liver, the liver-targeted IFN gene-transfer (MC.IFNλ3), instead of systemic administrating IFN repeatedly, provides a promising concept for the treatment of chronic HBV infection. Minicircle DNA (dpeaa)DE-He213 Type III interferon (dpeaa)DE-He213 Interferon-stimulated gene (dpeaa)DE-He213 Hepatitis B virus (dpeaa)DE-He213 Chen, Dianke aut Cai, Qingxian aut Huang, Zhanlian aut Xu, Wenxiong aut Peng, Liang aut Chen, Ping (orcid)0000-0003-0131-6499 aut Enthalten in BMC cell biology London : BioMed Central, 2000 21(2020), 1 vom: 18. Feb. (DE-627)326644830 (DE-600)2041486-9 1471-2121 nnns volume:21 year:2020 number:1 day:18 month:02 https://dx.doi.org/10.1186/s12860-020-00250-9 kostenfrei Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_11 GBV_ILN_22 GBV_ILN_2003 GBV_ILN_2008 GBV_ILN_2021 GBV_ILN_4305 AR 21 2020 1 18 02 |
| allfieldsGer |
10.1186/s12860-020-00250-9 doi (DE-627)SPR026940957 (SPR)s12860-020-00250-9-e DE-627 ger DE-627 rakwb eng Guo, Xiaoyan verfasserin aut Minicircle DNA vector expressing interferon-lambda-3 inhibits hepatitis B virus replication and expression in hepatocyte-derived cell line 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © The Author(s) 2020 Background Interferon-alpha (IFNα) is a first-line treatment option for chronic hepatitis B virus (HBV) infection, but the severe systemic side-effects limited its clinical application. Interferon-lambda (IFNλ) with comparable antiviral activity and less toxic side-effects is thought to be a good alternative interferon to IFNα. Additionally, the gene vector mediated sustainably expression of therapeutic product in the target cells/tissue may overcome the shortcomings resulted from the short half-life of IFNs. Results We constructed a liver-specific IFNλ3-expressing minicircle (MC) vector under the control of a hepatocyte-specific ApoE promoter (MC.IFNλ3) and investigated its anti-HBV activity in a HBV-expressing hepatocyte-derived cell model (HepG2.2.15). As expected, the MC.IFNλ3 vector capable of expressing IFNλ3 in the recipient hepatocytes has demonstrated robust anti-HBV activity, in terms of suppressing viral antigen expression and viral DNA replication, via activation the interferon-stimulated gene (ISG) expression in HepG2.2.15 cells. Conclusions Given the MC vector can be easily delivered into liver, the liver-targeted IFN gene-transfer (MC.IFNλ3), instead of systemic administrating IFN repeatedly, provides a promising concept for the treatment of chronic HBV infection. Minicircle DNA (dpeaa)DE-He213 Type III interferon (dpeaa)DE-He213 Interferon-stimulated gene (dpeaa)DE-He213 Hepatitis B virus (dpeaa)DE-He213 Chen, Dianke aut Cai, Qingxian aut Huang, Zhanlian aut Xu, Wenxiong aut Peng, Liang aut Chen, Ping (orcid)0000-0003-0131-6499 aut Enthalten in BMC cell biology London : BioMed Central, 2000 21(2020), 1 vom: 18. Feb. (DE-627)326644830 (DE-600)2041486-9 1471-2121 nnns volume:21 year:2020 number:1 day:18 month:02 https://dx.doi.org/10.1186/s12860-020-00250-9 kostenfrei Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_11 GBV_ILN_22 GBV_ILN_2003 GBV_ILN_2008 GBV_ILN_2021 GBV_ILN_4305 AR 21 2020 1 18 02 |
| allfieldsSound |
10.1186/s12860-020-00250-9 doi (DE-627)SPR026940957 (SPR)s12860-020-00250-9-e DE-627 ger DE-627 rakwb eng Guo, Xiaoyan verfasserin aut Minicircle DNA vector expressing interferon-lambda-3 inhibits hepatitis B virus replication and expression in hepatocyte-derived cell line 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © The Author(s) 2020 Background Interferon-alpha (IFNα) is a first-line treatment option for chronic hepatitis B virus (HBV) infection, but the severe systemic side-effects limited its clinical application. Interferon-lambda (IFNλ) with comparable antiviral activity and less toxic side-effects is thought to be a good alternative interferon to IFNα. Additionally, the gene vector mediated sustainably expression of therapeutic product in the target cells/tissue may overcome the shortcomings resulted from the short half-life of IFNs. Results We constructed a liver-specific IFNλ3-expressing minicircle (MC) vector under the control of a hepatocyte-specific ApoE promoter (MC.IFNλ3) and investigated its anti-HBV activity in a HBV-expressing hepatocyte-derived cell model (HepG2.2.15). As expected, the MC.IFNλ3 vector capable of expressing IFNλ3 in the recipient hepatocytes has demonstrated robust anti-HBV activity, in terms of suppressing viral antigen expression and viral DNA replication, via activation the interferon-stimulated gene (ISG) expression in HepG2.2.15 cells. Conclusions Given the MC vector can be easily delivered into liver, the liver-targeted IFN gene-transfer (MC.IFNλ3), instead of systemic administrating IFN repeatedly, provides a promising concept for the treatment of chronic HBV infection. Minicircle DNA (dpeaa)DE-He213 Type III interferon (dpeaa)DE-He213 Interferon-stimulated gene (dpeaa)DE-He213 Hepatitis B virus (dpeaa)DE-He213 Chen, Dianke aut Cai, Qingxian aut Huang, Zhanlian aut Xu, Wenxiong aut Peng, Liang aut Chen, Ping (orcid)0000-0003-0131-6499 aut Enthalten in BMC cell biology London : BioMed Central, 2000 21(2020), 1 vom: 18. Feb. (DE-627)326644830 (DE-600)2041486-9 1471-2121 nnns volume:21 year:2020 number:1 day:18 month:02 https://dx.doi.org/10.1186/s12860-020-00250-9 kostenfrei Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_11 GBV_ILN_22 GBV_ILN_2003 GBV_ILN_2008 GBV_ILN_2021 GBV_ILN_4305 AR 21 2020 1 18 02 |
| language |
English |
| source |
Enthalten in BMC cell biology 21(2020), 1 vom: 18. Feb. volume:21 year:2020 number:1 day:18 month:02 |
| sourceStr |
Enthalten in BMC cell biology 21(2020), 1 vom: 18. Feb. volume:21 year:2020 number:1 day:18 month:02 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| topic_facet |
Minicircle DNA Type III interferon Interferon-stimulated gene Hepatitis B virus |
| isfreeaccess_bool |
true |
| container_title |
BMC cell biology |
| authorswithroles_txt_mv |
Guo, Xiaoyan @@aut@@ Chen, Dianke @@aut@@ Cai, Qingxian @@aut@@ Huang, Zhanlian @@aut@@ Xu, Wenxiong @@aut@@ Peng, Liang @@aut@@ Chen, Ping @@aut@@ |
| publishDateDaySort_date |
2020-02-18T00:00:00Z |
| hierarchy_top_id |
326644830 |
| id |
SPR026940957 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR026940957</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230519230710.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">201007s2020 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1186/s12860-020-00250-9</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR026940957</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)s12860-020-00250-9-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Guo, Xiaoyan</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Minicircle DNA vector expressing interferon-lambda-3 inhibits hepatitis B virus replication and expression in hepatocyte-derived cell line</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2020</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">© The Author(s) 2020</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Background Interferon-alpha (IFNα) is a first-line treatment option for chronic hepatitis B virus (HBV) infection, but the severe systemic side-effects limited its clinical application. Interferon-lambda (IFNλ) with comparable antiviral activity and less toxic side-effects is thought to be a good alternative interferon to IFNα. Additionally, the gene vector mediated sustainably expression of therapeutic product in the target cells/tissue may overcome the shortcomings resulted from the short half-life of IFNs. Results We constructed a liver-specific IFNλ3-expressing minicircle (MC) vector under the control of a hepatocyte-specific ApoE promoter (MC.IFNλ3) and investigated its anti-HBV activity in a HBV-expressing hepatocyte-derived cell model (HepG2.2.15). As expected, the MC.IFNλ3 vector capable of expressing IFNλ3 in the recipient hepatocytes has demonstrated robust anti-HBV activity, in terms of suppressing viral antigen expression and viral DNA replication, via activation the interferon-stimulated gene (ISG) expression in HepG2.2.15 cells. Conclusions Given the MC vector can be easily delivered into liver, the liver-targeted IFN gene-transfer (MC.IFNλ3), instead of systemic administrating IFN repeatedly, provides a promising concept for the treatment of chronic HBV infection.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Minicircle DNA</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Type III interferon</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Interferon-stimulated gene</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Hepatitis B virus</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Chen, Dianke</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Cai, Qingxian</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Huang, Zhanlian</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Xu, Wenxiong</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Peng, Liang</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Chen, Ping</subfield><subfield code="0">(orcid)0000-0003-0131-6499</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">BMC cell biology</subfield><subfield code="d">London : BioMed Central, 2000</subfield><subfield code="g">21(2020), 1 vom: 18. Feb.</subfield><subfield code="w">(DE-627)326644830</subfield><subfield code="w">(DE-600)2041486-9</subfield><subfield code="x">1471-2121</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:21</subfield><subfield code="g">year:2020</subfield><subfield code="g">number:1</subfield><subfield code="g">day:18</subfield><subfield code="g">month:02</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1186/s12860-020-00250-9</subfield><subfield code="z">kostenfrei</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_11</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2003</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2008</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2021</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">21</subfield><subfield code="j">2020</subfield><subfield code="e">1</subfield><subfield code="b">18</subfield><subfield code="c">02</subfield></datafield></record></collection>
|
| author |
Guo, Xiaoyan |
| spellingShingle |
Guo, Xiaoyan misc Minicircle DNA misc Type III interferon misc Interferon-stimulated gene misc Hepatitis B virus Minicircle DNA vector expressing interferon-lambda-3 inhibits hepatitis B virus replication and expression in hepatocyte-derived cell line |
| authorStr |
Guo, Xiaoyan |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)326644830 |
| format |
electronic Article |
| delete_txt_mv |
keep |
| author_role |
aut aut aut aut aut aut aut |
| collection |
springer |
| remote_str |
true |
| illustrated |
Not Illustrated |
| issn |
1471-2121 |
| topic_title |
Minicircle DNA vector expressing interferon-lambda-3 inhibits hepatitis B virus replication and expression in hepatocyte-derived cell line Minicircle DNA (dpeaa)DE-He213 Type III interferon (dpeaa)DE-He213 Interferon-stimulated gene (dpeaa)DE-He213 Hepatitis B virus (dpeaa)DE-He213 |
| topic |
misc Minicircle DNA misc Type III interferon misc Interferon-stimulated gene misc Hepatitis B virus |
| topic_unstemmed |
misc Minicircle DNA misc Type III interferon misc Interferon-stimulated gene misc Hepatitis B virus |
| topic_browse |
misc Minicircle DNA misc Type III interferon misc Interferon-stimulated gene misc Hepatitis B virus |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
cr |
| hierarchy_parent_title |
BMC cell biology |
| hierarchy_parent_id |
326644830 |
| hierarchy_top_title |
BMC cell biology |
| isfreeaccess_txt |
true |
| familylinks_str_mv |
(DE-627)326644830 (DE-600)2041486-9 |
| title |
Minicircle DNA vector expressing interferon-lambda-3 inhibits hepatitis B virus replication and expression in hepatocyte-derived cell line |
| ctrlnum |
(DE-627)SPR026940957 (SPR)s12860-020-00250-9-e |
| title_full |
Minicircle DNA vector expressing interferon-lambda-3 inhibits hepatitis B virus replication and expression in hepatocyte-derived cell line |
| author_sort |
Guo, Xiaoyan |
| journal |
BMC cell biology |
| journalStr |
BMC cell biology |
| lang_code |
eng |
| isOA_bool |
true |
| recordtype |
marc |
| publishDateSort |
2020 |
| contenttype_str_mv |
txt |
| author_browse |
Guo, Xiaoyan Chen, Dianke Cai, Qingxian Huang, Zhanlian Xu, Wenxiong Peng, Liang Chen, Ping |
| container_volume |
21 |
| format_se |
Elektronische Aufsätze |
| author-letter |
Guo, Xiaoyan |
| doi_str_mv |
10.1186/s12860-020-00250-9 |
| normlink |
(ORCID)0000-0003-0131-6499 |
| normlink_prefix_str_mv |
(orcid)0000-0003-0131-6499 |
| title_sort |
minicircle dna vector expressing interferon-lambda-3 inhibits hepatitis b virus replication and expression in hepatocyte-derived cell line |
| title_auth |
Minicircle DNA vector expressing interferon-lambda-3 inhibits hepatitis B virus replication and expression in hepatocyte-derived cell line |
| abstract |
Background Interferon-alpha (IFNα) is a first-line treatment option for chronic hepatitis B virus (HBV) infection, but the severe systemic side-effects limited its clinical application. Interferon-lambda (IFNλ) with comparable antiviral activity and less toxic side-effects is thought to be a good alternative interferon to IFNα. Additionally, the gene vector mediated sustainably expression of therapeutic product in the target cells/tissue may overcome the shortcomings resulted from the short half-life of IFNs. Results We constructed a liver-specific IFNλ3-expressing minicircle (MC) vector under the control of a hepatocyte-specific ApoE promoter (MC.IFNλ3) and investigated its anti-HBV activity in a HBV-expressing hepatocyte-derived cell model (HepG2.2.15). As expected, the MC.IFNλ3 vector capable of expressing IFNλ3 in the recipient hepatocytes has demonstrated robust anti-HBV activity, in terms of suppressing viral antigen expression and viral DNA replication, via activation the interferon-stimulated gene (ISG) expression in HepG2.2.15 cells. Conclusions Given the MC vector can be easily delivered into liver, the liver-targeted IFN gene-transfer (MC.IFNλ3), instead of systemic administrating IFN repeatedly, provides a promising concept for the treatment of chronic HBV infection. © The Author(s) 2020 |
| abstractGer |
Background Interferon-alpha (IFNα) is a first-line treatment option for chronic hepatitis B virus (HBV) infection, but the severe systemic side-effects limited its clinical application. Interferon-lambda (IFNλ) with comparable antiviral activity and less toxic side-effects is thought to be a good alternative interferon to IFNα. Additionally, the gene vector mediated sustainably expression of therapeutic product in the target cells/tissue may overcome the shortcomings resulted from the short half-life of IFNs. Results We constructed a liver-specific IFNλ3-expressing minicircle (MC) vector under the control of a hepatocyte-specific ApoE promoter (MC.IFNλ3) and investigated its anti-HBV activity in a HBV-expressing hepatocyte-derived cell model (HepG2.2.15). As expected, the MC.IFNλ3 vector capable of expressing IFNλ3 in the recipient hepatocytes has demonstrated robust anti-HBV activity, in terms of suppressing viral antigen expression and viral DNA replication, via activation the interferon-stimulated gene (ISG) expression in HepG2.2.15 cells. Conclusions Given the MC vector can be easily delivered into liver, the liver-targeted IFN gene-transfer (MC.IFNλ3), instead of systemic administrating IFN repeatedly, provides a promising concept for the treatment of chronic HBV infection. © The Author(s) 2020 |
| abstract_unstemmed |
Background Interferon-alpha (IFNα) is a first-line treatment option for chronic hepatitis B virus (HBV) infection, but the severe systemic side-effects limited its clinical application. Interferon-lambda (IFNλ) with comparable antiviral activity and less toxic side-effects is thought to be a good alternative interferon to IFNα. Additionally, the gene vector mediated sustainably expression of therapeutic product in the target cells/tissue may overcome the shortcomings resulted from the short half-life of IFNs. Results We constructed a liver-specific IFNλ3-expressing minicircle (MC) vector under the control of a hepatocyte-specific ApoE promoter (MC.IFNλ3) and investigated its anti-HBV activity in a HBV-expressing hepatocyte-derived cell model (HepG2.2.15). As expected, the MC.IFNλ3 vector capable of expressing IFNλ3 in the recipient hepatocytes has demonstrated robust anti-HBV activity, in terms of suppressing viral antigen expression and viral DNA replication, via activation the interferon-stimulated gene (ISG) expression in HepG2.2.15 cells. Conclusions Given the MC vector can be easily delivered into liver, the liver-targeted IFN gene-transfer (MC.IFNλ3), instead of systemic administrating IFN repeatedly, provides a promising concept for the treatment of chronic HBV infection. © The Author(s) 2020 |
| collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_11 GBV_ILN_22 GBV_ILN_2003 GBV_ILN_2008 GBV_ILN_2021 GBV_ILN_4305 |
| container_issue |
1 |
| title_short |
Minicircle DNA vector expressing interferon-lambda-3 inhibits hepatitis B virus replication and expression in hepatocyte-derived cell line |
| url |
https://dx.doi.org/10.1186/s12860-020-00250-9 |
| remote_bool |
true |
| author2 |
Chen, Dianke Cai, Qingxian Huang, Zhanlian Xu, Wenxiong Peng, Liang Chen, Ping |
| author2Str |
Chen, Dianke Cai, Qingxian Huang, Zhanlian Xu, Wenxiong Peng, Liang Chen, Ping |
| ppnlink |
326644830 |
| mediatype_str_mv |
c |
| isOA_txt |
true |
| hochschulschrift_bool |
false |
| doi_str |
10.1186/s12860-020-00250-9 |
| up_date |
2024-07-03T23:33:55.854Z |
| _version_ |
1803602766969438208 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR026940957</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230519230710.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">201007s2020 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1186/s12860-020-00250-9</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR026940957</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)s12860-020-00250-9-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Guo, Xiaoyan</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Minicircle DNA vector expressing interferon-lambda-3 inhibits hepatitis B virus replication and expression in hepatocyte-derived cell line</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2020</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">© The Author(s) 2020</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Background Interferon-alpha (IFNα) is a first-line treatment option for chronic hepatitis B virus (HBV) infection, but the severe systemic side-effects limited its clinical application. Interferon-lambda (IFNλ) with comparable antiviral activity and less toxic side-effects is thought to be a good alternative interferon to IFNα. Additionally, the gene vector mediated sustainably expression of therapeutic product in the target cells/tissue may overcome the shortcomings resulted from the short half-life of IFNs. Results We constructed a liver-specific IFNλ3-expressing minicircle (MC) vector under the control of a hepatocyte-specific ApoE promoter (MC.IFNλ3) and investigated its anti-HBV activity in a HBV-expressing hepatocyte-derived cell model (HepG2.2.15). As expected, the MC.IFNλ3 vector capable of expressing IFNλ3 in the recipient hepatocytes has demonstrated robust anti-HBV activity, in terms of suppressing viral antigen expression and viral DNA replication, via activation the interferon-stimulated gene (ISG) expression in HepG2.2.15 cells. Conclusions Given the MC vector can be easily delivered into liver, the liver-targeted IFN gene-transfer (MC.IFNλ3), instead of systemic administrating IFN repeatedly, provides a promising concept for the treatment of chronic HBV infection.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Minicircle DNA</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Type III interferon</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Interferon-stimulated gene</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Hepatitis B virus</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Chen, Dianke</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Cai, Qingxian</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Huang, Zhanlian</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Xu, Wenxiong</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Peng, Liang</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Chen, Ping</subfield><subfield code="0">(orcid)0000-0003-0131-6499</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">BMC cell biology</subfield><subfield code="d">London : BioMed Central, 2000</subfield><subfield code="g">21(2020), 1 vom: 18. Feb.</subfield><subfield code="w">(DE-627)326644830</subfield><subfield code="w">(DE-600)2041486-9</subfield><subfield code="x">1471-2121</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:21</subfield><subfield code="g">year:2020</subfield><subfield code="g">number:1</subfield><subfield code="g">day:18</subfield><subfield code="g">month:02</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1186/s12860-020-00250-9</subfield><subfield code="z">kostenfrei</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_11</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2003</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2008</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2021</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">21</subfield><subfield code="j">2020</subfield><subfield code="e">1</subfield><subfield code="b">18</subfield><subfield code="c">02</subfield></datafield></record></collection>
|
| score |
7.399884 |